Bristol Myers Squibb Reports observational Data for Obinutuzumab in Head and neck cancer

Bristol Myers Squibb today announced observational results for obinutuzumab in patients with head and neck cancer. The study demonstrated that obinutuzumab improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of head and neck cancer and support the continued development of obinutuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.